Ovarian cancer: 3 randomised controlled phase III clinical trials presented at ESMO establish the benefit of PARP inhibition ...

Web

Oct. 3, 2019

SCIENTIFIC

Ovarian cancer.

3 randomised controlled phase III clinical trials presented at ESMO establish the benefit of PARP inhibition as upfront therapy in ovarian cancer. In all 3 trials, PFS improvement was greater for BRCA1/2 mutant patients

- Niraparib maintenance improved PFS for pts with platinum sensitive disease (13.8 vs 8.2 months, Rx vs placebo). Benefit enriched in (but not limited to) Myriad myChoice HRD+ pts (BRCA1/2 mutation + markers of homogous recombination) .ESMO LBA1 https://www.nejm.org/doi/full/10.1056/NEJMoa1910962 

- Olaparib maintenance improved PFS for pts with platinum sensitive disease when added to bevacizumab (22.1 vs 16.6 months respectively). Benefit enriched in BRCA1/2 mutant and Myriad myChoice HRD+ pts. ESMO LBA2_PR


- Veliparib added to upfront chemo and continued as maintenance improved PFS (23.5 vs 17.3 months); advantage was greater for BRCA1/2 mutant subset ( PFS 34.7 vs 22.0 months). ESMO LBA 3 | https://www.nejm.org/doi/pdf/10.1056/NEJMoa1909707